LIGAND PHARMACEUTICALS (LGND) Forecast, Price Target & Analyst Ratings
NASDAQ:LGND • US53220K5048
212.29 USD
+4.13 (+1.98%)
At close: Mar 10, 2026
215 USD
+2.71 (+1.28%)
After Hours: 3/10/2026, 8:00:03 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LIGAND PHARMACEUTICALS (LGND).
Forecast Snapshot
Consensus Price Target
$248.31
+ 16.97% Upside
Next Earnings Forecast
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate$1.88
Revenue Estimate61.049M
ChartMill Buy Consensus
85.71%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$248.31
Upside
+ 16.97%
From current price of $212.29 to mean target of $248.31, Based on 14 analyst forecasts
Low
$222.20
Median
$239.70
High
$288.75
Price Target Revisions
1 Month
0.00%
3 Months
2.50%
Price Target Summary
14 Wall Street analysts provided a forecast for the next 12 months for LGND. The average price target is 248.31 USD. This implies a price increase of 16.97% is expected in the next year compared to the current price of 212.29.
The average price target has been revised upward by 2.5% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.71%
LGND was analyzed by 14 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about LGND.
In the previous month the buy percentage consensus was at a similar level.
LGND was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-27 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-02-24 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-10 | Stifel | Maintains | Buy -> Buy |
| 2025-12-09 | Citigroup | Initiate | Buy |
| 2025-11-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-07 | Benchmark | Maintains | Buy -> Buy |
| 2025-11-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-03 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-03 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-02 | Benchmark | Maintains | Buy -> Buy |
| 2025-08-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-07-30 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-04-10 | Stifel | Initiate | Buy |
| 2024-12-23 | Benchmark | Reiterate | Buy -> Buy |
| 2024-12-16 | Barclays | Maintains | Overweight -> Overweight |
| 2024-12-11 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-12-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-11-08 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-11-08 | Benchmark | Maintains | Buy -> Buy |
| 2024-11-08 | Barclays | Maintains | Overweight -> Overweight |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 6, 2026
PeriodQ1 / 2026
EPS Estimate$1.88
Revenue Estimate61.049M
Revenue Q2Q34.67%
EPS Q2Q41.37%
Number of Analysts9
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.41%
EPS (1 Month)
0.00%
EPS (3 Months)
5.60%
Next Earnings Summary
LGND is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is 1.88 USD and the consensus revenue estimate is 61.05M USD.
The next earnings revenue estimate has been revised upward by 0.41% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 196.2M -29.20% | 131.314M -33.07% | 167.133M 27.28% | 246.87M 47.71% | 270.06M 9.39% | 321.47M 19.04% | 356.97M 11.04% | 408.08M 14.32% | 466.71M 14.37% | 551.53M 18.17% | 638.02M 15.68% | 702.35M 10.08% | |
| EBITDA YoY % growth | 54.5M -58.08% | 46.342M -14.97% | 58.26M 25.72% | 108.82M 86.78% | 178.98M 64.47% | 235.06M 31.33% | 214.68M -8.67% | 261.91M 22.00% | 331.59M 26.60% | 413.24M 24.62% | 480.87M 16.37% | N/A | |
| EBIT YoY % growth | 3M -96.20% | 9.821M 227.37% | 23.021M 134.41% | 50.211M 118.11% | 132.17M 163.23% | 168.45M 27.45% | 169.32M 0.52% | 187.32M 10.63% | 254M 35.60% | 318.41M 25.36% | 380.74M 19.58% | 361.71M -5.00% | |
| Operating Margin | 1.53% | 7.48% | 13.77% | 20.34% | 48.94% | 52.40% | 47.43% | 45.90% | 54.42% | 57.73% | 59.68% | 51.50% | |
| EPS YoY % growth | 4.28 -33.33% | 6.10 42.52% | 5.71 -6.39% | 7.73 40.81% | 8.49 5.61% | 9.81 15.56% | 10.51 7.12% | 11.48 9.17% | 14.80 28.98% | 17.15 15.85% | 18.97 10.65% | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 1.88 41.37% | 1.94 21.43% | 2.35 -23.99% | 2.51 24.22% |
| Revenue Q2Q % growth | 61.049M 34.67% | 64.703M 35.85% | 73.238M -15.71% | 77.436M 29.78% |
| EBITDA Q2Q % growth | 39.318M 240.98% | 42.12M 55.93% | 57.976M -27.22% | 63.059M 75.33% |
| EBIT Q2Q % growth | 29.438M 180.30% | 30.64M 215.23% | 46.512M -14.02% | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
9.34%
EPS Next 5 Year
12.98%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
13.08%
Revenue Next 5 Year
13.58%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
155.76%
EBIT Next 5 Year
79.51%
LIGAND PHARMACEUTICALS / LGND Forecast FAQ
What is the average price target for LIGAND PHARMACEUTICALS (LGND) stock?
14 analysts have analysed LGND and the average price target is 248.31 USD. This implies a price increase of 16.97% is expected in the next year compared to the current price of 212.29.
When does LIGAND PHARMACEUTICALS (LGND) report earnings?
LIGAND PHARMACEUTICALS (LGND) will report earnings on 2026-05-06.
What are the consensus estimates for LIGAND PHARMACEUTICALS (LGND) next earnings?
The consensus EPS estimate for the next earnings of LIGAND PHARMACEUTICALS (LGND) is 1.88 USD and the consensus revenue estimate is 61.05M USD.
How do analysts rate LIGAND PHARMACEUTICALS (LGND)?
The consensus rating for LIGAND PHARMACEUTICALS (LGND) is 85.7143 / 100 . This indicates that analysts generally have a positive outlook on the stock.